Generating real-world evidence is not the same as generating usable evidence. A pharmacoepidemiological study with rigorous methods, a well-governed dataset, and credible statistical analysis can still fail to support its intended regulatory or access purpose if the evidence package was not designed with the specific submission context in mind.
Regulatory agencies and HTA bodies assess RWE against explicit methodological and reporting standards that differ by jurisdiction and use case. EMA's Real-World Evidence Framework, NICE's RWE framework, IQWIG requirements for indirect comparisons in AMNOG dossiers, and HAS transparency requirements – each applies different thresholds and different expectations for study design, confounding control, and sensitivity analysis.
APICES helps sponsors connect their evidence generation activities to these specific frameworks from the start of study design. The goal is not to generate evidence and then position it for access – it is to design evidence that serves the access purpose, so that the final package is directly usable without reanalysis or methodological augmentation.
When real-world evidence is being generated to support a regulatory purpose – post-authorization safety study obligations, label extension support, managed entry agreement conditions, or comparative effectiveness data for an expedited pathway – the study design must meet regulatory standards that are more demanding than those applied to academic or market research.
Regulatory alignment is built into the study design, the statistical analysis plan, and the data governance framework before the study begins. This prevents the most common and expensive failure mode: an RWE study that generates good data but cannot be submitted because the design does not meet the specific regulatory standard.
Market access alignment requires understanding what evidence HTA bodies in your target markets actually need – not what the scientific literature considers methodologically ideal. APICES provides access alignment support specific to each HTA body and market:
How does APICES ensure RWE is aligned with EMA requirements?
Study design is reviewed against EMA PASS guidance, ENCePP Code of Conduct, and applicable product-specific guidance before the protocol is finalised. Post-hoc alignment is not accepted as standard practice.
Can APICES support HTA submissions in multiple European countries simultaneously?
Yes. We design evidence packages that can support HTA submissions across Germany (AMNOG), France (HAS), England (NICE), Italy (AIFA), and others in parallel, including the EU Joint Clinical Assessment process.
What is the difference between regulatory alignment and access alignment?
Regulatory alignment ensures the study meets regulatory authority standards for approval or pharmacovigilance purposes. Access alignment ensures the evidence supports payer formulary or reimbursement decisions. Both are needed for most late-stage programmes.
Do you support early benefit assessment evidence generation in Germany?
Yes. We design and execute comparative effectiveness studies structured to meet IQWIG M7 method requirements for indirect treatment comparisons used in AMNOG early benefit assessments.
Can APICES align a study with both FDA and EMA requirements?
Yes. For programmes with global development aspirations, we review design and analytical requirements for FDA real-world evidence guidance and EMA RWE frameworks simultaneously.
If you are preparing your next early clinical study or want to sanity-check how your program is set up, the next step is a focused conversation.
No packaged answers. Just context, experience, and a clear view on fit.
